# An Investigation to Identify the Anti-Cancer Properties of Novel Rhenium Compounds in Prostate and Lung Cancer Cell Lines

## TL;DR

This study explores new rhenium compounds for their potential to kill prostate and lung cancer cells and identifies specific pathways they affect.

## Contribution

The study introduces PR7, a rhenium compound, and reveals its impact on multiple cancer-related signaling pathways in lung cancer cells.

## Key findings

- PR7 significantly affects several cancer-related pathways in lung cancer cells.
- PR7 shows apoptotic effects on cancer cells as confirmed by Annexin-V and Tubulin tracker kits.
- Rhenium compounds in the PR series demonstrate toxicity in prostate cancer cell lines.

## Abstract

The anti-cancer properties of rhenium compounds have attracted researchers for decades. In this study, rhenium-based PR series compounds (PR1–PR10) were exposed to LNCaP and E006AA prostate cancer cell lines to verify their toxicities. Among the compounds, PR7 was tested further to determine its effects on the lung cancer cell lines A549 using RNA sequencing and Ingenuity Pathway Analysis (IPA) software. In this study, IPA analysis was explored further to determine that PR7 played a role in various canonical pathways. The pathways affected are: Ephrin Receptor Signaling, TGF-β Signaling, STAT3 Pathway, EGF Signaling, Tumor Microenvironment Pathway, BAG2 Signaling Pathway, H-17A Signaling Pathway, EIF2 Signaling. Annexin-V and Tubulin tracker kits identified the apoptotic capabilities of the PR series compounds